Sökning: onr:"swepub:oai:lup.lub.lu.se:363e19cf-3c68-4f76-9087-575db8d19cd2" >
Autoimmunity to sel...
-
Demircan, KamilBerlin Institute of Health (BIH),Humboldt University of Berlin
(författare)
Autoimmunity to selenoprotein P predicts breast cancer recurrence
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:363e19cf-3c68-4f76-9087-575db8d19cd2
-
https://lup.lub.lu.se/record/363e19cf-3c68-4f76-9087-575db8d19cd2URI
-
https://doi.org/10.1016/j.redox.2022.102346DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
BackgroundLow concentrations of serum selenium (Se) and its main transporter selenoprotein P (SELENOP) are associated with a poor prognosis following breast cancer diagnosis. Recently, natural autoantibodies (aAb) with antagonistic properties to SELENOP uptake have been identified in healthy subjects, and in patients with thyroid disease. Given the potential transport disrupting properties, we hypothesized that breast cancer patients with SELENOP-aAb may have a poor prognosis.MethodsSELENOP-aAb along with serum Se, SELENOP and GPX3 activity were determined in serum samples of 1988 patients with a new diagnosis of breast cancer enrolled in the multicentre SCAN-B study. Patients were followed for ∼9 years and multivariate Cox regression models were applied to assess hazard ratios.ResultsApplying a cut-off based on outlier detection, we identified 7.65% of patients with SELENOP-aAb. Autoantibody titres correlated positively to total Se and SELENOP concentrations, but not to GPX3 activity, supporting a negative role of SELENOP-aAb on Se transport. SELENOP-aAb were associated with age, but independent of tumor characteristics. After fully adjusting for potential confounders, SELENOP-aAb were associated with higher recurrence, HR(95%CI) = 1.87(1.17–2.99), particularly in patients with low Se concentrations, HR(95%CI) = 2.16(1.20–3.88). Associations of SELENOP-aAb with recurrence and mortality were linear and dose-dependent, with fully adjusted HR(95%CI) per log increase of 1.25(1.01–1.55) and 1.31(1.13–1.51), respectively.ConclusionOur results indicate a prognostic and pathophysiological relevance of SELENOP-aAb in breast cancer, with potential relevance for other malignancies. Assessment of SELENOP-aAb at time of diagnosis identifies patients with a distinctly elevated risk for a poor prognosis, independent of established prognostic factors, who may respond favourably to Se supplementation.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Sun, QianHumboldt University of Berlin,Berlin Institute of Health (BIH)
(författare)
-
Bengtsson, YlvaLund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Surgery,Lund University Research Groups,Skåne University Hospital(Swepub:lu)yl2813be
(författare)
-
Seemann, PetraHumboldt University of Berlin,SelenOmed GmbH,Berlin Institute of Health (BIH)
(författare)
-
Vallon-Christersson, JohanLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments(Swepub:lu)onk-jvc
(författare)
-
Malmberg, MartinSkåne University Hospital
(författare)
-
Saal, LaoLund University,Lunds universitet,Translational Oncogenomics,Forskargrupper vid Lunds universitet,Lund University Research Groups(Swepub:lu)onk-ls0
(författare)
-
Ryden, LisaLund University,Lunds universitet,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,The Liquid Biopsy och Tumörprogression i Bröstcancer,Breast Cancer Surgery,Lund University Research Groups,The Liquid Biopsy and Tumor Progression in Breast Cancer,Skåne University Hospital(Swepub:lu)pat-lry
(författare)
-
Minich, Waldemar B.Berlin Institute of Health (BIH),Humboldt University of Berlin
(författare)
-
Borg, ÅkeLund University,Lunds universitet,Familjär bröstcancer,Forskargrupper vid Lunds universitet,Familial Breast Cancer,Lund University Research Groups(Swepub:lu)onk-abo
(författare)
-
Manjer, JonasLund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Surgery,Lund University Research Groups,Skåne University Hospital(Swepub:lu)smi-jma
(författare)
-
Schomburg, LutzBerlin Institute of Health (BIH),Humboldt University of Berlin
(författare)
-
Berlin Institute of Health (BIH)Humboldt University of Berlin
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Redox Biology: Elsevier BV532213-2317
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Demircan, Kamil
-
Sun, Qian
-
Bengtsson, Ylva
-
Seemann, Petra
-
Vallon-Christers ...
-
Malmberg, Martin
-
visa fler...
-
Saal, Lao
-
Ryden, Lisa
-
Minich, Waldemar ...
-
Borg, Åke
-
Manjer, Jonas
-
Schomburg, Lutz
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Redox Biology
- Av lärosätet
-
Lunds universitet